SCHEMBL2865518

SCHEMBL2865518

CC(C)c1ccccc1-n1nc2c(c1N)c(=O)[nH]c1cc(OCCN3CCOCC3)ccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.50
PDGFRB P09619 2/20 0.50
KDR P35968 2/20 0.50
MAOA P21397 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 1/20 0.42
JAK2 O60674 1/20 0.42
PARP1 P09874 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA2B P29275 1/20 0.41
ADORA1 P30542 1/20 0.41
AURKA O14965 1/20 0.40
FGFR2 P21802 1/20 0.40
FGFR3 P22607 1/20 0.40
PDGFRA P16234 1/20 0.40
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
PDE9A O76083 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2865389 0.84 KDM4E (0.50) FGFR1PDGFRBKDRMAOAMEN1
SCHEMBL2858247 0.83 KDM4E (0.49) FGFR1PDGFRBKDRMAOAMEN1
SCHEMBL2862095 0.83 MAOA (0.47) FGFR1PDGFRBKDRMAOAKDM4E
SCHEMBL2864473 0.83 MAOA (0.47) FGFR1PDGFRBKDRMAOAMEN1
SCHEMBL2866738 0.83 MAOA (0.47) FGFR1PDGFRBKDRMAOAKDM4E
SCHEMBL2868766 0.83 KDM4E (0.51) FGFR1PDGFRBKDRMAOAMEN1
SCHEMBL2861641 0.81 JAK2 (0.50) FGFR1PDGFRBKDRMAOAKDM4E
SCHEMBL2868613 0.81 FGFR1 (0.49) FGFR1PDGFRBKDRMAOAKDM4E
SCHEMBL2866686 0.81 CSF1R (0.45) FGFR1PDGFRBKDRMAOAKDM4E
SCHEMBL2868581 0.80 KDM4E (0.49) FGFR1PDGFRBKDRMAOAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 FGFR1 201/4885PDGFRB 375/4885KDR 1226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.